GIMOTI is a dopamine-2 (D2) antagonist indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
Side Effects Of Gimoti
The most common adverse reactions (≥5%) are dysgeusia, headache, and fatigue.
Warnings & Precautions
GIMOTI is not recommend for use in:
- Pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in Neonates
- Patients with moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL/minute),
- Patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions.
Dosage Of Gimoti
Adults less than 65 years of age: The recommended dosage is 1 spray (15 mg) in one nostril, 30 minutes before each meal, and at bedtime (maximum of 4 sprays daily) for 2 to 8 weeks, depending on symptomatic response.
Adults 65 years of age and older: GIMOTI is not recommended in geriatric patients as initial therapy. Geriatric patients receiving an alternative metoclopramide product at a stable dosage of 10 mg four times daily can be switched to GIMOTI 1 spray (15 mg) in one nostril, 30 minutes before each meal and at bedtime (maximum four times daily) for 2 to 8 weeks, depending on symptomatic response.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use GIMOTI for a condition for which it was not prescribed. Do not give GIMOTI to other people, even if they have the same symptoms that you have. It may harm them.
You can ask your pharmacist or healthcare provider for information about GIMOTI that is written for health professionals.
All information has been provided courtesy of MedLinePlus from the National Library of Medicine and from the FDA.